Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07276789 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
A Phase 2 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Integro Theranostics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07276789 is a Phase 2 study of Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by Integro Theranostics. The registered enrollment target is 35 participants, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07276789, a Phase 2 study of Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by Integro Theranostics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) infusion in patients undergoing VATS (Video-Assisted Thoracoscopic Surgery) or RATS (Robotic-Assisted Thoracoscopic Surgery) resection of Stage I-II non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG LS301-IT 0.1 mg/kg
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07276789
The ClinicalTrials.gov registry entry for NCT07276789 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (88% lower). The listed sponsor is Integro Theranostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which LS301-IT 0.1 mg/kg is the first listed.
NCT07276789 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07276789 about?
NCT07276789 is a clinical study titled "Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer". The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) infusion in patients undergoing VATS (Video-Assisted Thoracoscopic Surgery) or RATS (Robot...
What is the current status of trial NCT07276789?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-12-08. Estimated completion is 2026-09.
What conditions does trial NCT07276789 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT07276789?
The interventions under investigation include: LS301-IT 0.1 mg/kg (DRUG).
Who is sponsoring clinical trial NCT07276789?
This trial is sponsored by Integro Theranostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07276789 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Pembrolizumab for Advanced NSCLC and PS 2-3
RECRUITING · Phase 2
-
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
ACTIVE NOT RECRUITING · Phase 2
-
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.